India’s CDMO (Contract Growth and Manufacturing Group) market is projected to develop from $15.63 billion in 2023 to $44.63 billion by 2029. This speedy progress is pushed by price benefits, technological developments, and a robust regulatory framework.
Providing 20 % decrease prices than China, India has develop into a key participant in world pharmaceutical outsourcing.
The rising demand for diversified provide chains has led to a 50 % surge in RFPs for Indian CDMOs in 2024. The nation can also be investing in high-growth therapies like cell and gene remedy (CAGR 45 %), antibody-drug conjugates (CAGR 25 %), and nucleic acid therapeutics (CAGR 36 %).
With the worldwide CDMO market projected to hit $465.14 billion by 2032, India is rising as a robust different to China, backed by a talented workforce and authorities initiatives like PLI schemes to spice up home manufacturing. Positioned for speedy enlargement, India is ready to reshape world pharmaceutical manufacturing.
Following are a couple of pharma shares in focus as India’s CDMO market targets $44.63 billion by 2029:
1. Divi’s Laboratories Restricted
With a market cap of Rs. 1.48 lakh crores, the inventory has moved up by about 1.6 % to Rs. 5,756.55 on BSE, throughout Thursday’s buying and selling session.
Divi’s Laboratories is growing a three-unit undertaking inside a 500-acre manufacturing facility in Kakinada, Andhra Pradesh. Section I, spanning 200 acres, commenced business operations in January 2025, reinforcing the corporate’s place in intermediates and customized synthesis options.
In Q3 FY25, the corporate’s income from operations elevated by round 25 per cent to Rs. 2,319 crores, whereas the web revenue grew by practically 64.5 % YoY to Rs. 589 crores.
2. Laurus Labs Restricted
With a market cap of Rs. 30,880.3 crores, the inventory has moved up by about 0.3 % to Rs. 586.1 on BSE, throughout Thursday’s buying and selling session.
The corporate’s CDMO phase achieved its highest quarterly gross sales up to now eight quarters, nearing Rs. 400 crore. On a nine-month foundation, the phase recorded a 33 % progress, pushed by robust demand and the scaling up of recent belongings.
In Q3 FY25, the corporate’s income from operations elevated by round 18.4 % to Rs. 1,415 crores, whereas the web revenue grew by practically 304.3 % YoY to Rs. 93 crores.
Additionally learn: Financial institution inventory through which mutual funds bought shares value over ₹1,600 Cr in February
3. Jubilant Pharmova Restricted
With a market cap of Rs. 13,780.2 crores, the inventory has moved up by about 3.2 % to Rs. 893.3 on BSE, throughout Thursday’s buying and selling session.
Beneath the CDMO Sterile Injectables, the corporate is a number one contract producer in North America, and serves as the highest world innovator pharma firm. In Q3 FY25, it launched new CDMO providers catering to biotech and huge pharmaceutical corporations.
In Q3 FY25, the corporate’s income from operations elevated by round 8.6 % to Rs. 1,822 crores, whereas the web revenue grew by practically 53 % YoY to Rs. 101 crores.
4. Dr Reddy’s Laboratories Restricted
With a market cap of Rs. 92,439.6 crores, the inventory has moved up by about 2 % to Rs. 1,125 on BSE, throughout Thursday’s buying and selling session.
In 2024, Aurigene Pharmaceutical Companies, a CRDMO arm of Indian pharmaceutical main Dr Reddy’s, established a biologics facility in Hyderabad’s Genome Valley to fabricate therapeutic proteins, antibodies, and viral vectors.
Operational since June 2024, the ability presents end-to-end providers, from medical analysis to business manufacturing.
In Q3 FY25, the corporate’s income from operations elevated by round 16 % YoY to Rs. 8,381 crores, whereas the web revenue grew marginally by practically 2 % YoY to Rs. 1,404 crores.
Written by Shivani Singh
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the creator are usually not accountable for any losses triggered because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
